AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of RAC-beta serine/threonine-protein kinase including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into RAC-beta serine/threonine-protein kinase therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of RAC-beta serine/threonine-protein kinase, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on RAC-beta serine/threonine-protein kinase. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of RAC-beta serine/threonine-protein kinase. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for RAC-beta serine/threonine-protein kinase includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
RAC-beta serine/threonine-protein kinase
partner:
Reaxense
upacc:
P31751
UPID:
AKT2_HUMAN
Alternative names:
Protein kinase Akt-2; Protein kinase B beta; RAC-PK-beta
Alternative UPACC:
P31751; B2RBD8; Q05BV0; Q0VAN0; Q0VAN1; Q68GC0
Background:
RAC-beta serine/threonine-protein kinase, also known as Protein kinase Akt-2, plays a pivotal role in cellular processes such as metabolism, proliferation, cell survival, growth, and angiogenesis. It achieves this through the phosphorylation of various substrates, including those involved in glucose uptake and glycogen storage, thereby regulating insulin signaling and glucose homeostasis.
Therapeutic significance:
Given its critical role in insulin signaling and glucose homeostasis, AKT2 is directly implicated in Type 2 diabetes mellitus and Hypoinsulinemic hypoglycemia with hemihypertrophy. Targeting AKT2's activity or its downstream effects presents a promising avenue for developing treatments for these metabolic disorders.
